Galderma Group AG is a Switzerland based holding Company, specializing in dermatological treatments and skin care products. The Company, throw its subsidiaries, operates a portfolio of carious self-care brands focusing primarily on dermatological solutions, through its subsidiaries. production within the portfolio include neuromodulators, fillers. and biostimulators. these products are designed to relax winkles via injection, fill wrinkles in a specific location via injection and stimulate the body's cells to function optimally. The production process, for the various products primarily takes place in house, form research and development to manufacturing. In addition, including education, scientific engagements, and other services are offered.

Employees

Sector

Personal Products

Calendar

06-21 - International Dermatology Congress

More about the company

Quotes

Date	Price	Change	Volume
25-06-19	112.10 CHF	+1.26%	219,880
25-06-18	110.70 CHF	+2.41%	304,232
25-06-17	108.10 CHF	-1.99%	320,748
25-06-16	110.30 CHF	-0.90%	385,783
25-06-13	111.30 CHF	-0.63%	327,717

Delayed Quote Swiss Exchange, June 19, 2025 at 11:31 am

More quotes

Income Statement and Estimates

More financial data

Ratings

Trading Rating

Investor Rating

ESG MSCI

BBB

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

136.85USD

Average target price

134.46USD

Spread / Average Target

-1.75%

Consensus

EPS Estimates

Revisions to estimates

Quarterly revenue - Rate of surprise

Company calendar

Market Closed - Swiss Exchange Other stock markets 11:31:37 2025-06-19 EDT			5-day change	1st Jan Change
112.10 ^CHF	+1.26%		+0.09%	+11.39%

Capitalization	32.49B 28.33B 26.61B 24.2B 44.63B 2,822B 50.34B 314B 121B 1,286B 122B 119B 4,735B	P/E ratio 2025 *	75.6x	P/E ratio 2026 *	44.3x
Enterprise value	34.37B 29.97B 28.16B 25.61B 47.22B 2,986B 53.26B 332B 128B 1,360B 129B 126B 5,010B	EV / Sales 2025 *	6.99x	EV / Sales 2026 *	5.96x
Free-Float	35.38%	Yield 2025 *	0.2%	Yield 2026 *	0.35%

Galderma Announces Data from New Interim Analysis of Study Investigating the Long-Term Safety and Efficacy of Nemluvio in Moderate-To-Severe Prurigo Nodularis	06-18	CI
Galderma Group AG - New Data Demonstrate Nemluvio®'S (Nemolizumab) Favorable Safety Profile	06-18	RE
Galderma Publishes New Data On Nemluvio's Safety Profile	06-18	RE
Swiss stocks - Factors to watch on June 18	06-18	RE
Galderma Establishes New U.S. Headquarters In Miami	06-17	RE
Galderma Establishes New U.S. Headquarters in Miami and Strengthens Regional Leadership	06-17	CI
Galderma?S Nemluvio® (Nemolizumab) Receives National Institute for Health and Care Excellence Recommendation for Moderate-To-Severe Atopic Dermatitis in England and Wales	06-12	CI
Galderma's Atopic Dermatitis Drug Gets Backing for Routine NHS Funding	06-12	MT
Galderma Announces Two-Year Data from A New Interim Analysis of A Long-Term Extension Study Investigating the Safety and Efficacy of Nemluvio in Moderate-To-Severe Atopic Dermatitis	06-06	CI
Galderma Says Long-Term Data On Nemluvio (Nemolizumab) Demonstrate Its Favorable Safety Profile	06-06	RE
Swiss stocks - Factors to watch on June 6	06-06	RE
EQT sells shares in German company Galderma	06-04
EQT Wraps Up CHF1.86 Billion Sale of Galderma Shares	06-03	MT

RBC Capital Downgrades Galderma to Sector Perform, Lifts PT	03-10	MT
RBC Capital Lifts Price Target on Galderma Group, Maintains Outperform Recommendation	24-09-24	MT
JP Morgan Starts Galderma Coverage at Overweight	24-08-09	MT
Bank Vontobel Begins Galderma Coverage with Buy Rating	24-07-03	MT

ICD 2025: New data demonstrate Nemluvio®’s (nemolizumab) favorable safety profile and sustained and clinically meaningful improvements in symptoms of prurigo nodularis up to two years	06-18	BU
Galderma’s Nemluvio® (nemolizumab) Receives National Institute for Health and Care Excellence (NICE) Recommendation for Moderate-to-severe Atopic Dermatitis in England and Wales	06-12	BU
RAD 2025: Long-Term Data on Nemluvio® (nemolizumab) Demonstrate its Favorable Safety Profile and Sustained and Increased Improvements in Itch and Skin Lesions in Patients With Atopic Dermatitis up to Two Years	06-06	BU
EQT completes sale of shares in Galderma Group AG	06-03	AQ
Galderma Buys Back Shares Worth CHF 233 Million in the Context of Accelerated Bookbuild Offering	05-28	BU

Galderma Group AG Stock

Equities

GALD

CH1335392721

Personal Products

Valuation: Galderma Group AG

Chart: Galderma Group AG

Latest news: Galderma Group AG

Last Transcript: Galderma Group AG

Analysts' recommendations: Galderma Group AG

Press Releases: Galderma Group AG

News in other languages: Galderma Group AG

Quotes and Performance

Course Extremes

Cosmetics & Perfumes

Financials

Company Profile

Quotes

Income Statement and Estimates

Ratings

Analysts' Consensus

Quarterly revenue - Rate of surprise

Should I Stay or Should I go ?	06-18
Aktien Schweiz Vorbörse: Nahost-Krise hat Märkte vor Fed im Griff	06-18
Morning Briefing - Markt Schweiz	06-18
Bourse : Airbus au centre du jeu, nouvelle Xbox et piratage chez UBS	06-18
Galderma präsentiert neue Langzeitdaten zu Hoffnungsträger Nemluvio	06-18

1 day	+1.26%
1 week	+0.09%
Current month	+4.09%
1 month	+11.65%
3 months	+16.31%
6 months	+16.53%
Current year	+11.39%

1 week	107.4	112.5
1 month	98.4	117
Current year	72.7	119.6
1 year	64.75	119.6
3 years	60	119.6
5 years	60	119.6
10 years	60	119.6

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
GALDERMA GROUP AG	+1.26%	+0.09%	+47.38%	-	32.17B
L'ORÉAL	-1.73%	-3.89%	-17.65%	+18.19%	228B
KAO CORPORATION	+0.40%	-1.21%	-1.18%	+26.82%	21.48B
SHISEIDO COMPANY, LIMITED	+0.80%	+1.21%	-46.94%	-51.25%	6.82B
AMOREPACIFIC CORPORATION	+1.14%	-1.70%	-25.28%	-4.44%	5.96B
PROYA COSMETICS CO.,LTD.	-1.46%	-4.20%	-25.71%	-29.83%	4.51B
INTERPARFUMS, INC.	-1.89%	-6.16%	+19.37%	+100.14%	4.27B
COTY INC.	-3.04%	-4.77%	-50.97%	-31.96%	4.18B
ODDITY TECH LTD.	-1.68%	-5.66%	+79.16%	-	3.89B
SHANGHAI CHICMAX COSMETIC CO., LTD.	-4.18%	+0.69%	+48.30%	-	3.46B
Average	-1.03%	-1.87%	+2.65%	+3.95%	31.44B
Weighted average by Cap.	-1.21%	-2.85%	-8.79%	+16.37%

	2025 *	2026 *
Net sales	4.92B 4.29B 4.03B 3.66B 6.76B 427B 7.62B 47.54B 18.35B 195B 18.46B 18.06B 717B	5.65B 4.93B 4.63B 4.21B 7.76B 491B 8.76B 54.63B 21.09B 224B 21.21B 20.76B 824B
Net income	440M 384M 361M 328M 605M 38.25B 682M 4.26B 1.64B 17.43B 1.65B 1.62B 64.19B	740M 646M 607M 552M 1.02B 64.31B 1.15B 7.16B 2.76B 29.3B 2.78B 2.72B 108B
Net Debt	1.88B 1.64B 1.54B 1.4B 2.59B 164B 2.92B 18.21B 7.03B 74.55B 7.07B 6.92B 275B	1.19B 1.04B 973M 885M 1.63B 103B 1.84B 11.48B 4.43B 46.99B 4.46B 4.36B 173B